Skip to main content

. 1961 Jun;20(2):161–172. doi: 10.1136/ard.20.2.161

A Controlled Trial of Phenylbutazone, Oxyphenbutazone, and a Placebo in the Treatment of Rheumatoid Arthritis

R I Meanock ^1,^2,³, E Lewis-Faning ^1,^2,³

PMCID: PMC1007200 PMID: 13768783

165

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

BURNS J. J., ROSE R. K., GOODWIN S., REICHENTHAL J., HORNING E. C., BRODIE B. B. The metabolic fate of phenylbutazone (butazolidin) in man. J Pharmacol Exp Ther. 1955 Apr;113(4):481–489. [PubMed] [Google Scholar]
CARDOE N. Controlled trial of G27 202 (p-hydroxyphenyl-butazone) in rheumatoid arthritis. Ann Rheum Dis. 1959 Sep;18:244–248. doi: 10.1136/ard.18.3.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
GRAHAM W. The status of G-27202 (metabolite 1 of phenylbutazone) in the treatment of rheumatic disorders. Can Med Assoc J. 1960 May 14;82:1005–1008. [PMC free article] [PubMed] [Google Scholar]
HART F. D., BURLEY D. Phenylbutazone and its derivatives with special reference to G.27202. Br Med J. 1959 Apr 25;1(5129):1087–1089. doi: 10.1136/bmj.1.5129.1087. [DOI] [PMC free article] [PubMed] [Google Scholar]
SPERLING I. L. Untoward effects of phenylbutazone (butazolidin)-a re-evaluation. Arthritis Rheum. 1959 Jun;2(3):203–211. doi: 10.1002/1529-0131(195906)2:3<203::aid-art1780020303>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
VAUGHN P. P., HOWELL D. S., KIEM I. M. The comparative effects of phenylbutazone and G27202 (metabolite I) in patients with rheumatoid arthritis: an assessment of methods for antirheumatic drug evaluation. Arthritis Rheum. 1959 Jun;2(3):212–223. doi: 10.1002/1529-0131(195906)2:3<212::aid-art1780020304>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES